Synbio Technologies’s Voice: COVID-19: Computational Approaches as Emerging Methods

Recently, Pharma Tech Outlook’s website published an article about Computational Approaches as Emerging Methods, which was written by Dr. Lee of Synbio Technologies.

During the tough times of 2020, the SARS-Cov-2 virus that caused COVID-19 took tens of thousands lives. About a year later, we are still unable to make exact predictions about timelines of pandemics and the post-pandemic outlook. However, 2020 was an enormous leap for synthetic biology, as the breakthrough of mRNA vaccines brought us surprise and hope.

As the world has learned the lessons of the COVID-19 pandemic, Dr. Lee shared his opinion about new technologies and platforms in demand for fast and effective research.

“Therapeutic antibodies have become one of the predominant treatments for various diseases such as autoimmune, infectious diseases, cancer, and inflammation over the past 25 years. Currently, there are around 600 therapeutic antibodies in clinical trials as of the early 2020. Establishing a viable antibody candidate can take time and could cost up to tens of millions of dollars. A high failure rate of the traditional path also has prompted the need for computational and informatics approaches. Computational protocols should be extremely useful especially given the explosion of “omic data” available”.

Moreover, “computational downstream analysis such as antibody/protein modeling, TCR epitope prediction, antibody-antigen docking can provide a significant impact in streamlining antibody discovery process for years to come”.

See more here: https://www.pharmatechoutlook.com/vp/synbio-technologies/covid-19:_computational_approaches_as_emerging_methods/